Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo

BACKGROUND: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Nanomedicine
Autors principals: Lee, Chen-Hung, Hsieh, Ming-Jer, Chang, Shang-Hung, Hung, Kuo-Chun, Wang, Chao-Jan, Hsu, Ming-Yi, Juang, Jyuhn-Huarng, Hsieh, I-Chang, Wen, Ming-Shien, Liu, Shih-Jung
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6751553/
https://ncbi.nlm.nih.gov/pubmed/31686818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S211898
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars